
Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.
The company reported third-quarter sales of $11.37 billion, slightly missing the consensus of $11.40 billion. The U.S. MedTech giant reported adjusted earnings of $1.30, in line with Wall Street estimates and within the management guidance of $1.28-$1.32.